The main objective of this study was to investigate the feasibility of using PharmGKB, a pharmacogenomic database, as a source of training data in combination with text of MEDLINE abstracts for a text mining approach to identification of potential gene targets for pathway-driven pharmacogenomics research. We used the manually curated relations between drugs and genes in PharmGKB database to train a support vector machine predictive model and applied this model prospectively to MEDLINE abstracts. The gene targets suggested by this approach were subsequently manually reviewed. Our quantitative analysis showed that a support vector machine classifiers trained on MEDLINE abstracts with single words (unigrams) used as features and PharmGKB relations used for supervision, achieve an overall sensitivity of 85% and specificity of 69%. The subsequent qualitative analysis showed that gene targets ''suggested'' by the automatic classifier were not anticipated by expert reviewers but were subsequently found to be relevant to the three drugs that were investigated: carbamazepine, lamivudine and zidovudine. Our results show that this approach is not only feasible but may also find new gene targets not identifiable by other methods thus making it a valuable tool for pathway-driven pharmacogenomics research.
Introduction
Adverse Drug Reactions (ADRs) are responsible for 5.3% of hospital admissions and cost over 100 billion dollars per year due to prolonged hospital stays and decreased productivity making reduction in ADRs one of the top priority areas in health care and health services research [1] . One of the promising areas in biomedical research that can help reduce ADRs and enable more precise and rational dosing of medications based on individual patient characteristics is pharmacogenomics. Inter-individual variability in genetic makeup contributes significantly to observed variation in treatment response. The exact same dose of a medication may be ineffective in one individual and highly toxic in another due to this variation in treatment response. Some of the differences in drug response are due to inherited genetic polymorphisms in genes involved in absorption, distribution, metabolism and excretion (ADME) of drugs. Presence of genetic polymorphisms in the ADME genes can contribute to inter-individual differences in drug levels and hence response and/or toxicity. Additionally, genetic polymorphisms in drug targets and downstream signaling pathways (pharmacodynamics) could impart therapeutic response.
For example, differences in genetically conditioned drug metabolism were found to be responsible for the central nervous system toxicity in some patients treated with standard doses of an antineoplastic agent fluorouracil. These patients had an inherited deficiency in dihydropyrimidine dehydrogenase, an enzyme that metabolizes fluorouracil. Findings like these have given rise to the field of pharmacogenomics and individualized medicine [2] . Two major approaches for studying the relationship between genes and the variability in drug-response are genome-wide association studies (GWASs) and pathway driven approaches.
GWAS approaches explore the association between drug response and genome-wide genetic variation. However, one of the challenges for most GWAS studies is the high rate of false positives due to massive multiple comparisons made within smaller underpowered studies. In contrast, pathway driven approaches to studying the relationship between genes and the variability in drug-response require identification of candidate genes and/or pathways known to be important for drug pharmacokinetics and pharmacodynamics. While a large amount of information necessary to identify biologically plausible gene targets is contained in curated databases such as PharmGKB, much of this information still remains 'locked' in the unstructured text of biomedical publications. Emerging scientific evidence does not become immediately available in curated databases such as PharmGKB and is likely to appear earlier in unstructured text resources such as MEDLINE. Thus, the development of improved techniques to identify these candidate genes and/or pathways in published literature is an important area of research.
A large body of work in text mining and biomedical natural language processing (NLP) has been dedicated to extracting useful information from the pharmacogenomic literature (see Garten, Coulet and Altman [3] for a comprehensive review). Several studies specifically have examined the use of text mining methods such as automatic text categorization from PharmGKB and MEDLINE abstracts to automatically identify and categorize relations between genes, drugs and disorders [4, 5] . The study by Garten, Tatonetti and Altman [5] introduces a method by which a text processing system Pharmspresso [4] was used to identify pharmacogenomic relationships between genes and drugs extracted from full text of biomedical articles. Pharmspresso-extracted drug-gene relations encoded at a single sentence level were then used to automatically generate a network graph of drug-gene interactions. The output of Pharmspresso was thus used in a network analysis algorithm PGxPipeline that leverages the network connectivity to score the propensity of the genes to modulate drug response. The creation of the network using the automated approach based on Pharmspresso was subsequently compared to a network created from the manually curated PharmGKB database and found to be roughly equivalent. However, when the authors evaluated the performance of Pharmspesso independently of the PGxPipeline, they found that Pharmspresso identified 5312 pharmacogenomic relations, while PharmGKB contained 1782 relations with an overlap between the two sources of 1157. These results show that Pharmspresso is a relatively sensitive (recall of 65%) but not highly specific (precision of 22%) tool for extracting individual drug-gene relations. Similarly to PGxPipeline but without the use of free-text extraction, Hansen et al. [6] have developed an approach to using structural similarity between drugs and information on their interactions contained in structured form in PharmGKB to train an automatic classifier for predicting the most likely novel gene candidates that may interact with drugs of interest. Another study by Coulet et al. [7] relied on text mining and Natural Language Processing techniques to extract drug-gene relation information from MEDLINE to construct an ontological network of relations that may be used in guiding the curation of pharmacogenomic resources such as PharmGKB.
In our current study, we also investigated the use of text mining algorithms for extracting pharmacogenomic relations from the biomedical literature. However, the main difference between our approach and that of Garten et al. [5] is that we used the manually curated knowledge of drug-gene relations and linked this to PubMed abstracts contained in PharmGKB itself to train a fully supervised machine learning classifier using the text of the abstracts as a source of training features and PharmGKB-defined relations as the source of category information (related vs. unrelated). The main objective of our study is to investigate if MEDLINE abstracts with mention of both drugs and genes contain lexical and semantic indicators of either presence or absence of a functional relationship between the drug-gene pair that may be used to identify biologically plausible gene targets. Our hypothesis is that the language in the MEDLINE abstract that surrounds the mention of drugs and genes (lexical context) is predictive of whether the abstract as a whole is asserting some form of relationship between the drug and the gene and is generalizable across multiple drugs.
If the context is indeed generalizable and can be modeled with standard machine learning approaches, then it would be feasible to construct a tool that can be used to examine MEDLINE abstracts on a regular basis (or on demand) to classify abstracts containing drug-gene pairs as related or unrelated in order to make suggestions for possible gene targets for pathway driven pharmacogenomic research.
Methods
In this paper, we describe the use of PharmGKB to both train and evaluate simple automatic drug-gene relationship classifiers and present the results of a prospective evaluation study in which the gene targets identified by our approach were examined by pharmacogenomics experts using three drugs: carbamazepine, lamivudine and zidovudine. The choice of these specific drugs was motivated by the fact that their pathways have been recently analyzed by our group, but the results of the analysis have not yet been included in PharmGKB. The overall study design is illustrated in Fig. 1. 
Data
We used 822 drugs and 2247 genes labeled as 'Related' (those marked as 'Related' or 'Positively Related') or 'Unrelated' (those marked as 'Negatively Related', 'Discussed', or 'Not Related') in PharmGKB. While these relations in PharmGKB are not always consistently labeled, generally, positively related drug-gene pairs indicate that there is evidence for a pharmacokinetic or pharamcodynamic relationship between the gene and the drug while a negatively related pair indicates that the drug has been found to have no interaction with the target gene and should, therefore, be treated as 'Unrelated'. The dataset consists of 9317 instances of drug-gene pairs and the MEDLINE abstracts in which the pairs occurred where each drug contained on average 11.3 instances with a maximum of 394 (methotrexate) and a minimum of 1 (4-methylthioamphetamine).
Machine learning
Apart from the choice of the learning algorithm, two additional processes are generally important in the context of text mining: feature extraction and feature selection. Feature extraction refers to the process of identifying relevant features in unstructured text. Feature sets extracted from text can be very large, especially if a non-selective feature extraction approach such as bag-of-words is used. Selecting features that are most relevant and predictive of the categories into which text is being categorized has been shown to improve classification accuracy [8] .
Feature extraction
We explored the use of lexical features in a supervised learning approach to labeling the drug-gene pairs as related or unrelated using the support vector machine (SMO) from the WEKA data-mining package [9] .
Lexical features consisted of words or n-grams (sequences of words) that frequently occured in the training data. We used unigrams (single words -equivalent to the bag-of-words approach) and bigrams (two word sequences) in our current study, but with larger datasets it may be beneficial to experiments with larger n-gram sizes. The names of the drugs and the genes found in all PharmGKB drug-gene pairs were excluded from modeling to make it context independent of any specific drug-gene pair in order to be able to apply the resulting model prospectively to any drug-gene pair. These drug and gene names were excluded by removing them from the text of MEDLINE abstracts prior to modeling. The noncontent words (stopwords) are not included as features. The stopword list used in these experiments contained 9900 general English non-content words 1 . We used two frequency cutoffs to determine if a unigram or bigram should be included in the feature set. The frequency cutoffs were implemented by counting the number of times in which a unigram or bigram occurred in the same abstract as the drug-gene pair. For this work, we used a conservative cutoff of two for both unigrams and bigrams. Thus, for example in (1), the set of unigrams included, evidence, suggests, substrates and induced.
(1) Evidence suggests that CYP2C9 substrates may also be induced by carbamazepine.
Feature selection
We relied on WEKA's implementation of the Information Gain feature selection method. Information gain is a measure of the contribution of each predictive feature to correctly predicting the category [9] . Information gain reflects the degree by which the uncertainty/entropy associated with determining the correct classification category is reduced by learning the value of a given variable. This measure is frequently used in machine learning to determine which features or sets of features to use for automatic categorization. In our case, the information gain from a single word for the related or unrelated categories would be zero if there is no contribution of the feature to distinguishing between related and unrelated exemplars, thus we used this as the threshold to select only those features with positive contribution. Information gain is a convenient feature selection method as its computation is relatively fast and thus lends itself better to classification problems that involve large numbers of features and multiple iterations; however, other more sophisticated feature selection methods may result in further improvements in classification results.
Evaluation platform
We evaluated our approach using two methods: (a) hold-oneout evaluation using only PharmGKB data and (b) prospective extraction of drug-gene relations from MEDLINE with subsequent manual validation.
PharmGKB-based evaluation
We evaluated our approach using a modification of the holdone-out validation method as illustrated in Fig. 1 . In this method, all available data were divided into 822 blocks where each block was associated with a specific drug. We then tested our method using one held-out drug-block, training on the remaining 821 drug-blocks. This procedure was repeated for each of the 822 drugs such that each drug-block has been used as test data exactly once with the remaining data used as training data. The operating characteristics (sensitivity, specificity, positive and negative predictive value) were averaged over all 822 blocks. Many of the drug blocks contained very few instances of drug-gene relations that could potentially result in biased overall estimates. To examine the impact of this potential source of bias, we also averaged the results over the top 15 drug blocks containing more than 20 samples. The process of hold-one-out validation on a large number of drugs was time consuming; therefore, we experimented with different feature extraction methods (unigrams vs. bigrams) on a smaller random sample of 110 drugs rather than the entire set of 822 drugs.
Prospective manual evaluation
We also evaluated our approach prospectively by applying a support vector machine model trained on all 822 drug blocks to classify all available 2010 MEDLINE Baseline 2 abstracts in which we found at least one mention of carbamazepine, lamovudine or zidovudine and any of the 2247 the gene names contained in PharmGKB. At this preliminary evaluation stage, we used a simple string matching approach to identifying drug and gene names but we are aware that drug and gene names can be ambiguous and that more sophisticated approaches to their identification exist [10] . At this point in our study we wanted to be as inclusive of the potential gene targets as possible and thus relied on disambiguating gene names (e.g. CAT -in the sense of ''CAT scan'' vs. ''chloramphenicol acetyl transferase'') during the manual evaluation step rather than trying to filter out non-gene senses prior to evaluation. We also selected only those genes for each drug that were automatically classified as related to the drug and presented these results to a set of three reviewers with expertise in pharmacogenomics. The experts have been involved in the pathway driven analysis of these three drugs and thus were familiar with the drugs and the gene candidates that were included in the drugs' metabolic pathways. In fact, the drugs for this evaluation were specifically selected from a set of drugs whose pathway information has been recently submitted to PharmGKB but had not appeared in the snapshot of the database used in our study. These reviewers were asked to mark each drug-gene pair hypothesized to be related by our automatic classification approach as related or unrelated. Using this evaluation approach we were only able to estimate the positive predictive value (PPV); however, the intended practical use of our approach is to provide pharmacogenomics researchers with recommendations for possible gene targets to be examined during the pathway driven analysis. Thus, we consider the PPV to be of more practical significance than any other operating characteristics. The intent of this evaluation step was also to determine if the reviewers with expertise in the pharmacogenomics of the three drugs of interest would find any related drug-gene pairs that they would not have been aware of otherwise.
Based on the results of the manual annotations, we conducted a sensitivity analysis in which we calculated PPV with and without filtering the output of the automatic classifier for gene names. At this preliminary stage, the filtering consisted on manually examining each gene name acronym that was marked as related to each of the three drugs in the context of the abstract in which the acronym was found. If the context of the abstract suggested that the acronym did not represent a gene name, that instance was then removed from the classifier output and was not included in calculating the filtered PPV value. Thus the filtered PPV value represents an estimate of the automatic classifier performance subsequent to a highly accurate gene-name identification algorithm. We report both filtered and unfiltered PPV values in the Results section.
Comparison to existing PharmGKB entries
In addition to the manual validation described in the previous section, we also compared the output of our classification approach to the contents of PharmGKB with respect to each of the three drugs. The entries contained in the snapshot of PharmGKB that was used to train the automatic classifier are shown in Table 1 . 
Results

PharmGKB-based evaluation
The performance of the algorithms was evaluated using standard measures of sensitivity and specificity as well as positive and negative predictive value (PPV/NPV) to reflect for variable prevalence of categories in the individual drug datasets.
Top fifteen drugs with at least 20 instances in the PharmGKB database are summarized in Table 2 along with means for two other sets consisting of a random sample of 110 drug blocks used to compare unigram and bigram feature extraction methods and a full set of all 822 drugs. The detailed results for each drug in the full result set are available at http://rxinformatics.umn.edu. The results in Table 2 for the random sample of 110 drug blocks show that the classifiers trained on unigrams were on average more specific than the classifiers trained on bigrams (0.69 vs. 0.46), while the latter were more sensitive (0.96 vs. 0.85). Thus for the next step in our evaluation involving human review of potential gene targets classified as ''related'' by the automatic classifier, we took into account the ''related'' category prevalence and selected the more specific unigram classifier that yielded slightly higher PPV of 0.91 vs. 0.89 obtained with the classifier trained on bigrams.
Prospective manual evaluation
Evaluating the automatic classifier approach on a larger set of only related drug-gene pairs for PPV resulted in estimates shown in Table 3 . For carbamazepine, the overlap between the set of genes labeled by the automatic classifier as ''related'' and those labeled as ''related'' in the manually curated PharmGKB database contains nine gene names. As evident from Table 3 , the automatic classifier ''suggested'' 54 gene targets for this drug, of which 18 were deemed by at least one expert as relevant.
Thus the classifier effectively ''discovered'' nine new relevant gene targets (100% increase relative to information contained in PharmGKB) and missed three gene targets that were in PharmGKB. For zidovudine, PharmGKB contained only one ''related'' gene target and this gene was also identified as ''related'' by the automatic classifier. However, the classifier suggested a total of 21 targets, eleven of which were deemed by experts to be relevant resulting in ten new automatically ''discovered'' targets (1000% relative increase). A slightly different result was obtained with lamivudine -PharmGKB contained one related gene that was missed by the automatic classifier for reasons discussed in the Discussion section. However, the automatic classifier produced a total of 16 new targets, six of which were deemed by experts to be relevant thus resulting in all six being novel viable targets not present in PharmGKB (600% relative increase).
Qualitative evaluation of the genes found with our approach
We conducted a qualitative analysis of two anti-retroviral medications we have investigated in this study -zidovudine and lamivudine. The list of genes indicated by our approach as potentially related to the drug was manually examined by experts in pharmacogenomics (JL, VL, YG, NB) to identify the ''novel'' genes 
Table 3
Results of prospective manual evaluation for carbamazepine, lamivudine and zidovudine. The results are shown before and after manually resolving ambiguous acronyms that were initially identified as gene names but removed after their meaning was determined to be something other than a gene name. that had not been considered by them in prior work. Our algorithm identified nine genes (ABCG2, ATP7A, CCR5, HFE, TG, SLC28A1 and UGT1A7, UGT1A9, UGT2B7) that were related to zidovudine. Manual evaluation of the literature annotations provided strong evidence for these genes in zidovudine pharmacokinetic and pharmacodynamic pathway. Fig. 2 shows an example of a pathway-driven analysis for zidovudine that was performed independently of the current study. The targets along the pathways shown in Fig. 2 have been experimentally confirmed and recently submitted to PharmGKB. The thick arrows in Fig. 2 indicate some of the potential targets that were suggested by the automatic classification approach. Some of the overlapping genes identified by both methods include UGT2B7, SLC28A1 and ABCG2. Additionally our analysis identified some new genes such as HFE, hematochromatosis gene, which has been implicated in antiretroviral treatment induced neuropathy (PMID: 18419350). It is possible that manual analysis to identify candidate PK/PD pathway genes for zidovudine would have missed association of this gene with the drug-induced adverse reaction. Similarly our analysis identified four genes that were related to lamivudine, another anti-retroviral drug. These included drug transporters ABCG2 and SLC28A1, and drug metabolizing enzymes CYP1A2 and CYP2C19.
Discussion
We have presented a novel approach for using standard machine learning and data mining techniques to leverage the existing manually curated pharmacogenomics information contained in PharmGKB. The results of the hold-one-out evaluation suggest that contextual information contained in MEDLINE abstracts captured with a simple bag-of-words approach can be used to determine if the abstracts containing mentions of medications and genes provide evidence of some form of relatedness between the gene and the drug. The fact that the mean sensitivity and specificity characteristics for all 822 drug blocks are comparable to the results obtained with the top 15 drug blocks with more than 20 training samples in them alleviate our initial concerns with relatively small numbers of samples available for each drug. The comparison between two feature extraction methods -one based on unigrams and the other on bigrams -suggests that the unigram approach is Fig. 2 . Illustration of the metabolic pathway analysis for zidovudine with thick arrows indicating targets identified by the automatic classifier. more specific but less sensitive than the bigram approach. Thus in an application where the automatic classification approach is used to suggest potential gene targets, it may be beneficial to use the unigram feature set on drugs with better known metabolic pathways (potentially large numbers of MEDLINE abstracts) in order to reduce the investigator's workload. However, in situations where it is more important to capture as many potential gene targets as possible regardless of the workload involved in filtering out false positives, it may be more beneficial to use the bigram feature set.
Applying our unigram-based approach trained on PharmGKB in a simulation of a ''prospective'' study to all of MEDLINE abstracts resulted in finding many more potentially relevant gene targets that were deemed to be useful by pharmacogenomics experts. The practical significance of these findings is that this approach may be used as a way to recommend potential gene targets to support the initial stages of pathway driven pharmacogenomics research on an on-going basis with little or no human intervention aside from the data being entered into PharmGKB. Since our approach is fully automated, it can easily keep up with the rapid growth of both PharmGKB and the MEDLINE abstracts repository. Our method may be used to provide potentially complementary information to other manually or semi-automatically curated resources for pharmacogenomics and drug metabolism research such as those provided by the Ingenuity Systems (http://www. ingenuity.com/) and SuperCYP (http://bioinformatics.charite.de/ supercyp/). Another potential application of our approach is in combination with Pharmspresso or other rule-based text mining algorithms providing input to network analytic systems such as PGxPipeline.
Our methodology may also be useful as a verification mechanism in helping investigators identify potential problems with the evidence provided for the presence or absence of a relationship between drugs and genes. For example, Table 1 shows that genes CYP2E1 and CYP3A were originally entered into PharmGKB as unrelated to carbamazepine and the gene SLC28A1 was marked as unrelated to zidovudine; however, our automatic classification approach marked these drug-gene pairs as related and this was subsequently confirmed by manual review. These examples demonstrate that scientific knowledge of the interactions between drugs and genes is in constant flux and accurate and up-to-date information extraction requires flexible and scalable text mining methods to keep up with the rapid growth of evidence presented in biomedical literature.
Limitations
For the work presented in this paper we relied exclusively on PharmGKB and MEDLINE as sources of training and testing data. Other sources containing text and information useful for our approach exist and may be utilized. For example, MEDLINE abstracts may be complemented with the full text of biomedical articles in PubMed Central and other repositories. Our methodology may need to be modified to work on the full text of biomedical articles and will likely need to take into account article section information.
For lamivudine, the snapshot of PharmGKB database that we used for this study contained only one gene marked as ''related'' -ABCC4. Our classification approach failed to find this relationship because neither the gene name ABCC4 or MRP4 were used in any of the available PubMed abstracts. Interestingly, on manual examination of PharmGKB database, the review article cited as evidence for the relationship between lamovudine and ABCC4 gene (PubMed ID: 16462814) does not contain either ABCC4 or MRP4 either in the abstract or in the main body of the paper. Both of these names (ABCC4 and MRP4), however, do appear in the References section of the article and the evidence for this relationship is actually contained in these cited articles. This example points out a potential limitation of using PharmGKB for mining drug-gene association where the investigator that enters the data into PharmGKB has the knowledge of the drug-gene relationship but does not necessarily verify that the article provided as evidence contains the actual relationship rather than indirectly pointing to another source of information. While this is a limitation, it can also be considered a strength as our methodology may be useful as a verification mechanism in helping investigators identify potential problems with the evidence provided for the presence or absence of a relationship between drugs and genes.
The focus of the current study was on determining if PharmGKB could be used as a source of training data to automatically find gene targets related to a given drug. Since most of the gene and gene product names are abbreviated, that introduces a large amount of ambiguity. For this paper, we manually disambiguated gene names to determine the impact of ambiguity on the accuracy of gene target identification. However, a number of word sense disambiguation algorithms targeted specifically to acronyms in clinical and biomedical discourse [11] [12] [13] [14] and gene names in particular [10] have been developed. In future work it will be necessary to integrate acronym and word sense ambiguity resolution as either a pre-or a post-processing step during gene classification.
Conclusions
Our results indicate the feasibility of using PharmGKB as a source of training data for machine learning to identify likely gene targets for pathway driven approaches in pharmacogenomics. This approach may be used iteratively to keep up with the growing volume of scientific literature and reduce the burden of manual searches for potential gene targets. More importantly, using our approach, pharmacogenomics investigators engaged in pathwaydriven analysis may also be able to identify gene targets that they would not be able to identify using other standard search methods.
